Avila Therapeutics Inc. has named Andrew Hirsch, former Biogen Idec vice president of corporate strategy and M&A, as chief financial officer of the Waltham biotech startup.

During his previous tenure at Biogen Idec, Hirsch held a number of financial positions and also worked as program executive in neurology, heading development of the company’s Tysabri, Avonex and BG-12 programs. Prior to that, he worked for a software startup, leading business development. Hirsch earned an MBA from the Tuck School at Dartmouth College and a bachelor’s degree in economics from the University of Pennsylvania.

SOURCE